daily coverage of the optics & photonics industry and the markets that it serves
Featured Showcases
Photonics West Showcase

‘Laser fabric’ treats skin diseases

22 Feb 2018

Wearable photodynamic therapy system said to improve patient experience in addressing acne, psoriasis and AK.

French scientists at Texinov Medical Textiles have developed a knitted laser fabric that can treat skin diseases such as acne, psoriasis, and actinic keratosis with light.

Chronic skin conditions can now be treated in a single 150 minute appointment with a wearable laser-bandage called Fluxmedicare that delivers light directly to the skin.

Fluxmedicare has been developed in collaboration with a pan-European health consortium PHOS-ISTOS. Following successful clinical trials, the painless laser fabric will be the quickest device to the market, says the developer, which adds that the laser bandage “will be used to eradicate unwanted skin conditions, with no side effects”.

Initially developed to improve the treatment of actinic keratosis (AK) – rough, scaly patches on the skin that develop from years of exposure to the sun – the light emitting textile is said to “be able to treat and even cure a number of skin complaints such as acne, Paget’s disease, psoriasis, and other diseases like baby jaundice”.

The systems works by covering the affected area with a photosensitizer cream then wrapping the skin with the light-emitting textile. Optical fibers knitted into the fabric then speed up the reaction between oxygen and photosensitizer cream beneath the skin.


Dr Nadege Boucard, R&D General Manager at Texinov commented, “Fluxmedicare is unprecedented in the field of treating skin conditions. Since the lighting textile wraps around the individual contours of a patient, the emitted light in our device is uniform at every part of the body under treatment, meaning the beams are homogenous.”

An earlier technology used to treat skin ailments such as AK was photodynamic therapy (PDT), in which a patient stands by a lamp delivering its light from a flat pane. With the intensity of the treatment, this technology could cause severe pain and even redness in the skin, says Texinov.

“We haven't changed the approach of the actual PDT treatment. PDT treatment was already existing and is efficient, so we have kept it as it is. What we have changed is the light "support". We transfer it from rigid panel to comfortable textile,” added Dr Boucard.

“Previous PDT was unsatisfactory in many ways. Not only did patients report a pain ranking of at least 7/10 as well as burns and redness persisting for several days, but also, coming from a flat source, a lot of the emitted light was lost.”

Painless therapy

During the clinical trials with INSERM Onco Thai Lab-CHRU Lille and Klinikum Vest in Germany, patients reported an average pain ranking on the FLUXMEDICARE device of between 0 and 1 out of ten. The official clinical trial report is still being put together and will be published by the investigator CHRU Lille.

“The fact that we had a near 90% drop in pain levels compared to the previous technology, and the same efficacy was really promising. Fluxmedicare is easy to use for both the patient and the clinician,” said Dr Boucard.

“The Fluxmedicare device comes relatively cheap. The earlier PDT system would cost anything from €15,000 for the lamp and protective gear and require a dedicated set-up in a hospital room or within a dermatologist’s surgery. However, our laser system currently costs around €5,000.

“The FLUXMEDICARE device is flexible and mobile so a number of patients can be treated simultaneously. In the future in we hope to treat people in their own homes. The implied healthcare savings are substantial,” Dr Boucard said.

The PHOS-ISTOS consortium secured a grant of €2.39 million from the European Commission under the CIP funding program, and is comprised of participants from five European countries: (France) Institut National de la Sante et de la Recherche Medicale, Centre Hospitalier de Lille, EREO Sas, Ecole Nationale Superieure Arts Industries Textiles, Universite de Lille II – Droit et Sante, Deltaval Sarl; (Germany) Klinikum Vest Gmbh; (Finland) Fluence Theraputics OY, Modulight OY; (Italy) Consorzio per la Promozione della Cultura Plastica Proplast; (Netherlands) Reden B.V.

The team at PHOS-ISTOS expects to have their product ready for commercial uptake in April 2018.

Mad City Labs, Inc.AlluxaCHROMA TECHNOLOGY CORP.Universe Kogaku America Inc.TRIOPTICS GmbHABTechLASEROPTIK GmbH
© 2024 SPIE Europe
Top of Page